Drug Search Results
More Filters [+]

Narlaprevir

Alternative Names: narlaprevir
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Russia

Approved Indications: None

Known Adverse Events: None

Company: R-Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Narlaprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hepatitis C, Chronic|Hepatitis A

Phase 1: Hepatitis C, Chronic|Cross Infection|Coinfection|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CJ05013053

P2

Completed

Hepatitis C, Chronic|Hepatitis A

2020-04-08

24%

CJ05013046

P2

Completed

Hepatitis C, Chronic|Hepatitis A

2018-08-29

22%

CJ05013019

P1

Completed

Hepatitis C, Chronic|Coinfection|Cross Infection

2017-06-24

PIONEER

P3

Completed

Hepatitis A|Hepatitis C, Chronic

2016-03-23

46%

Recent News Events